Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Propranolol for the Treatment of Adult Patients with Kaposi Sarcoma

Trial Status: active

This phase II trial tests how well propranolol works in treating adult patients with Kaposi sarcoma. Propranolol is a drug that is classified as a beta-blocker. Beta-blockers affect the heart and circulation (blood flow through arteries and veins). Propranolol has anti-angiogenic properties, meaning it may prevent the formation of blood vessels. In anticancer therapy, drugs with anti-angiogenic properties may prevent the growth of new blood vessels that tumors need to grow.